Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2023-07-01
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Investigate the relationship between H. pylori and CKD, in order to determine whether an association exists between H.pylori and kidneys.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The prevalence according to a study conducted by Ankouane et al. in Yaoundé (Cameroon) is up to 72.5% in hospital \[3\]. The main route of transmission is person to person transmission and often occurs in the first 5 years of life \[4\].
Helicobacter pylori is the most common human chronic infection, causing gastrointestinal diseases such as gastric malignancies, gastritis, and ulcerative diseases. H. pylori can also be involved in other non-gastrointestinal infections such as diabetes and metabolic syndrome, heart disease, hematologic disorders, cancer, and chronic kidney disease (CKD) as well as chronic renal failure (CRF) \[5\].
The risk factors for infection with H. pylori are low socioeconomic level, promiscuity, family history of H. pylori infection or gastritis, alcohol consumption, smoking \[6\].
The stomach is reported to be associated with conditions affecting other organs. Such as, an association between atrophic gastritis (AG) and coronary artery disease has been described, with AG representing a potential independent risk factor for coronary artery disease \[7\].
The diagnosis of H. pylori is made by noninvasive methods (the rapid urease test, the breath test, serology, stool antigen test) or invasive methods biopsy-based tests (culture and histology) \[8\]. The gold standard is histology, but current methods have been developed, using high-definition endoscopy \[9\].
Chronic kidney disease (CKD) is a growing disease and public health problem worldwide \[10\]. Gastrointestinal (GI) symptoms are common among subjects with CKD, and their intensity vary slightly to very severe, altering the quality of life and potentially hindering the effectiveness of the treatment \[11\] and also affects their nutrition status leading to the development of malnutrition, which is a potent predictor of morbidity and mortality \[12\].
Patients with chronic renal failure (CRF) often have gastrointestinal symptoms caused not only by H. pylori infection, but also by high urea levels, decline of gastrointestinal motility, hypergastrinemia and high ammonia levels \[10-13\].
Moreover, patients with CRF may have higher risks of gastric mucosal damages compared with individuals with normal renal function because of systemic and/or local chronic circulatory failure \[14\].
Epidemiological studies have revealed a link between H. pylori with insulin resistance and metabolic syndrome , which may increase the risk of CKD. However, up to date there is no conclusive evidence regarding the association between H. pylori infection and CKD \[15\].
A previous study reported that individuals infected with H. pylori had a higher risk of subsequent renal dysfunction than those not infected \[12\]. Conversely, the H. pylori infection rate is lower in patients with peptic ulcer disease and concomitant chronic kidney disease (CKD) than in those without CKD \[13\]. However, the relationship between H. pylori infection and/or gastric disorders and CKD has not been elucidated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
H. Pylori in CKD patients
100 0f patients with H.pylori with ckd according to GFR more than 60 according to kdigo guide lines
kidney function tests
using GFR test according to kdigo guide lines
H.pylori in normal renal function
100 of patients with H.pylori with normal renal function according to GFR less than 60 according to kdigo guide lines
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
kidney function tests
using GFR test according to kdigo guide lines
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 100 of them are CKd with GFR less than 60 according to kdigo guidelines
* 100 of them are normal renal function with GFR more than 60 according to kdigo guidelines
Exclusion Criteria
* History of gastrectomy
* Used proton-pump inhibitor. Patients with Past or present history of malignancy
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
hanaa zakaria william
resident of nephrology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abd elhamid Mohammed
Role: STUDY_DIRECTOR
Assiut University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H.pylori in CKD patients
Identifier Type: -
Identifier Source: org_study_id